Marker Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.5M | $6.6M | $3.3M | $3.5M | $0 |
| Research and development | $11.8M | $13.5M | $10.4M | $12.0M | $27.8M |
| Operating expenses | $16.4M | $17.7M | $17.9M | $23.3M | $40.7M |
| Operating income | -$12.9M | -$11.1M | -$14.6M | -$19.8M | -$39.5M |
| Pretax income | -$12.2M | -$10.7M | -$14.0M | -$19.8M | — |
| Income tax expense | -$15,156 | $49,953 | $3,675 | — | — |
| Net income | -$12.2M | -$10.7M | -$8.2M | -$29.9M | -$41.9M |
| Balance Sheet | |||||
| Cash and equivalents | $16.1M | $19.2M | $15.1M | $11.8M | $42.4M |
| Current assets | $19.1M | $22.0M | $17.1M | $16.6M | $46.0M |
| Total assets | $19.1M | $22.0M | $17.1M | $34.4M | $68.1M |
| Current liabilities | $2.3M | $3.5M | $3.1M | $7.8M | $12.9M |
| Total liabilities | $2.3M | $3.5M | $3.1M | $14.8M | $24.1M |
| Stockholders' equity | $16.8M | $18.6M | $14.1M | $19.6M | $44.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$12.0M | -$10.9M | -$16.4M | -$27.0M | -$27.3M |
| Depreciation and amortization | — | — | — | $2.8M | $2.1M |
| Stock-based compensation | $537,540 | $245,864 | $858,269 | $3.3M | $6.0M |
| Capital expenditure | — | — | — | $57,607 | $2.2M |
| Free cash flow | — | — | — | -$27.0M | -$29.4M |
Shares outstanding 16.7M · Free float 50.8%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.